Related Experiment Videos
Oral glycoprotein IIb/IIIa antagonists in coronary artery disease
1Department of Cardiology, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Insights
Oral glycoprotein IIb/IIIa inhibitors show limited success in chronic coronary artery disease management, unlike their intravenous counterparts. Further research is needed to understand the underlying mechanisms beyond platelet function.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Intravenous glycoprotein IIb/IIIa inhibitors are effective in percutaneous coronary intervention and acute coronary syndromes.
- Oral glycoprotein IIb/IIIa inhibitors have not demonstrated similar success in chronic coronary artery disease management.
Purpose of the Study:
- To explore the reasons behind the differing efficacy of intravenous versus oral glycoprotein IIb/IIIa inhibition.
- To investigate potential mechanisms, beyond platelet inhibition, that may explain the outcomes of oral glycoprotein IIb/IIIa inhibitor trials.
Main Methods:
- Review of clinical trial data for oral glycoprotein IIb/IIIa inhibitors in chronic coronary artery disease.
- Analysis of proposed factors such as dosing, inhibition levels, and platelet pro-coagulant activity.
- Exploration of potential alternative mechanisms suggested by discordant ischemic endpoint results.
Main Results:
- The efficacy of oral glycoprotein IIb/IIIa inhibition in chronic management is significantly less than intravenous forms.
- Factors like dosing and inadequate platelet inhibition have been proposed but do not fully explain the disparity.
- Observed discordant effects on ischemic endpoints suggest a mechanism possibly unrelated to platelet function.
Conclusions:
- The discrepancy between intravenous and oral glycoprotein IIb/IIIa inhibitor outcomes in coronary artery disease remains largely unexplained.
- A mechanism independent of platelet function may be implicated in the observed results of oral glycoprotein IIb/IIIa inhibitor trials.
- Further investigation is required to elucidate the enigmatic differences in clinical application and outcomes.
Abstract:
Despite the efficacy of intravenous glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention and those presenting with acute coronary syndromes, the application of oral glycoprotein IIb/IIIa inhibition to the chronic management of coronary artery disease has not met with the same success. To explain these results, factors related to dosing, and inadequate inhibition or activation of platelet pro-coagulant activity have been recently suggested. However, although the disparity between intravenous and oral glycoprotein IIb/IIIa experience remains largely enigmatic, the discordant effect on ischemic endpoints observed within the phase III oral glycoprotein IIb/IIIa inhibitor trials potentially implicates a mechanism unrelated to platelet function.